Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Mepolizumab...

    Mepolizumab significantly reduces exacerbation in Severe Eosinophilic Asthma

    Written by Vinay Singh singh Published On 2018-09-22T19:28:33+05:30  |  Updated On 22 Sept 2018 7:28 PM IST
    Mepolizumab significantly reduces exacerbation in Severe Eosinophilic Asthma

    A new study published in the Journal of Allergy and Clinical Immunology found that in patients with severe eosinophilic asthma (SEA) having similar blood eosinophil counts, mepolizumab was associated with significantly greater improvements in clinically significant exacerbations and asthma control compared with reslizumab or benralizumabin.


    William Busse et al. conducted a study to compare the efficacy of licensed doses of mepolizumab, benralizumab and reslizumab in patients with the SEA.


    Currently, 3 anti-interleukin (IL)5 pathway-directed treatments (benralizumab, mepolizumab, reslizumab) have been approved by the Food and Drug Administration for the treatment of severe asthma with an eosinophilic phenotype.


    The researchers extracted the data from the Cochrane review of anti-IL5 pathway-directed therapies developed in severe asthma. Studies eligible for inclusion in the indirect treatment comparison (ITC) were required to meet a pre-defined PICOS (Population; Intervention; Comparator; Outcomes; Study Design) framework.


    The populations consisted of patients with SEA aged ≥12 years. Interventions included only those assessing approved doses or formulations of licensed anti-IL5 pathway-directed treatments (mepolizumab 100 mg subcutaneously [SC] 4 weekly [Q4W]; reslizumab 3 mg/kg Q4W; benralizumab 30 mg Q8W [3x 4 weekly doses followed by 8 weekly dosing]). The comparators included placebo only. The outcomes included in the analysis were clinically significant exacerbations.


    Key study findings:




    • Compared with placebo, all treatments significantly reduced the rate of clinically significant exacerbations in each baseline blood eosinophil threshold subgroup.

    • However, only mepolizumab and reslizumab significantly reduced the rate of exacerbations requiring ER visit/hospitalization.

    • When comparing treatments against one another, mepolizumab significantly reduced the rate of clinically significant exacerbations compared with benralizumab and among patients with baseline blood eosinophil counts ≥400 cells/µL.

    • There was no difference in exacerbation reduction between reslizumab and benralizumab.

    • In patients with baseline blood eosinophils ≥150 cells/µL and ≥300 cells/µL, mepolizumab significantly reduced the rate of clinically significant exacerbations compared with benralizumab

    • For exacerbations requiring ER visit/hospitalization, no significant differences were observed between any two treatments in any subgroup assessed.


    Read Also: Tezepelumab designated as breakthrough therapy for Severe Asthma


    The study concluded that Mepolizumab significantly reduced the rate of clinically significant exacerbations by 34%–45% compared with benralizumab across all baseline blood eosinophil count thresholds, and by 45% compared with reslizumab in the ≥400 cells/µL subgroup.


    “The aim of this analysis was to provide relevant information based upon comparative phenotypic characteristics for clinicians to help inform treatment choices for patients with SEA and our results show statistically significant improvements in ACQ score with mepolizumab, benralizumab and reslizumab versus placebo in all subgroups assessed”, write the authors.


    For reference log on to http://10.1016/j.jaci.2018.08.031

    benralizumabinBloodeosinophillexacerbationsindirect treatment comparisonITCJournal of Allergy and Clinical ImmunologymepolizumabpatientsreslizumabSEAsevere eosinophilic asthmaWilliam Busse
    Source : With inputs from Journal of Allergy and Clinical Immunology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok